तुलना करने के लिए मीट्रिक्स | ELVN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधELVNपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −24.0x | −2.7x | −0.5x | |
PEG अनुपात | −7.43 | 0.13 | 0.00 | |
क़ीमत/बुक | 5.4x | 2.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 281.7x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 24.7% | 38.1% | 47.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 11.3% | 6.2% | अनलॉक करें |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.